Istituto Europeo Di Oncologia
Milan, Italy
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Medical Intelligence Core
Centri e Trial
Modulo Medical Intelligence Core.
Centri e trial per nazione
Catalogo server-side delle sedi dichiarate negli studi sul carcinoma mammario presenti in ClinicalTrials.gov. La presenza in un trial non equivale a una certificazione generale del centro.
6000 sedi globali indicizzate · 2484 trial · 31 nazioni aggiornate · ultimo aggiornamento 2026-09-30 12:36:46 UTC
Istituto Europeo Di Oncologia
Milan, Italy
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Istituto Europeo Di Oncologia
Milan, Italy
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
Istituto Europeo Di Oncologia
Milan, Italy
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Istituto Europeo Di Oncologia
Milan, Italy
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Istituto Europeo Di Oncologia
Milan, Italy
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Istituto Europeo Di Oncologia
Milan, Italy
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Istituto Europeo Di Oncologia
Milan, Italy
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Istituto Europeo Di Oncologia
Milan, Italy
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Istituto Europeo Di Oncologia
Milan, Italy
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Istituto Europeo Di Oncologia
Milan, Italy
PALbociclib CoLlaborative Adjuvant Study
Istituto Europeo Di Oncologia
Milan, Italy
Endoscopic Video-Assisted Nipple-Sparing Mastectomy
Istituto Europeo Di Oncologia
Milan, Italy
GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting
Istituto Europeo Di Oncologia
Milan, Italy
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Istituto Europeo Di Oncologia
Milan, Italy
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Istituto Europeo Di Oncologia
Milan, Italy
Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
Istituto Europeo Di Oncologia
Milan, Italy
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
Istituto Europeo Di Oncologia
Milan, Lombardy, Italy
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Istituto Europeo Di Oncologia
Milan, Lombardy, Italy
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Istituto Europeo Di Oncologia
Milan, Lombardy, Italy
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Azienda Ospedaliera Universitaria Federico II
Naples, Campania, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Azienda Ospedaliera Universitaria Federico II
Naples, Campania, Italy
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE
Naples, Campania, Italy
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS
Reggio Emilia, Emilia-Romagna, Italy
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Ospedale Infermi AUSL della Romagna
Rimini, Emilia-Romagna, Italy
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Policlinico Universitario Agostino Gemelli
Rome, Lazio, Italy
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Asst Degli Spedali Civili Di Brescia
Brescia, Lombardy, Italy
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Istituto Clinico Humanitas
Rozzano, Lombardy, Italy
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Humanitas Centro Catanese Di Oncologia
Misterbianco (CT), Sicily, Italy
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Ospedale Civile
Livorno, Tuscany, Italy
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
IOV - Istituto Oncologico Veneto - IRCCS
Padova, Veneto, Italy
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Novartis Investigative Site
Bari, BA, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Bergamo, BG, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Bologna, BO, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Florence, FI, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Genova, GE, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Milan, MI, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Rozzano, MI, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Palermo, PA, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Padova, PD, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Aviano, PN, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Roma, RM, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Terni, TR, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Investigative Site
Naples, Italy
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, Italy
A Master Regulator of Lipid-Associated Macrophage Function in Cancer
lstituto Nazionale Tumori IRCCS - Fondazione Pascale U.O.C. Oncologia Medica Senologica
Naples, Campania, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
IRCCS Ospedale Policlinico, San Martino
Genoa, Liguria, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
ASST Monza Ospedale San Gerardo Centro Ricerca di Fase 1
Monza (MB), Lombardy, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Humanitas lstituto Clinico Catanese
Catania (CT), Sicily, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Azienda Ospedaliero Universitaria delle Marche SOD Clinica Oncologica
Torrette, The Marches, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Divisione Oncologia Medica, Ospedale di Trento - Presidio Ospedaliero (PO) Santa Chiara
Trento, Trentino-Alto Adige, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
SOC Farmacia, Ospedale di Trento - Presidio Ospedaliero (PO)
Trento, Trentino-Alto Adige, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Oncologia Medica Azienda Usl Toscana Nord Ovest - Ospedali Riuniti di Livor
Livorno, Tuscany, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
S.O.C. Oncologia Medica - Nuovo Ospedale di Prato Santo Stefano
Prato, Tuscany, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
SSD Oncologia Medica Addarii - Zamagni, Policlinico Sant'Orsola - Malpighi
Bologna, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Istituto Clinico Humanitas
Milan, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Divisione di Senologia Medica; Istituto Europeo di Oncologia
Milan, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
UOC di Oncologia Medica, Azienda Ospedaliero Universitaria (AOU) di Parma
Parma, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Istituti Clinici Scientifici Maugeri IRCCS
Pavia, Italy
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Istituto Clinico Humanitas
Rozzano, Italy
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Istituto Clinico Humanitas
Rozzano, Italy
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Istituto Clinico Humanitas
Rozzano, Italy
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Azienda Ospedaliero Universitaria delle Marche
Ancona, Italy
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Istituto Di Candiolo
Candiolo (TO), Italy
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Istituto Scientifico Romagnolo
Meldola (FC), Italy
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Ospedale San Raffaele S.r.l.
Milan, Italy
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Humanitas Istituto Clinico Catanese S.p.A.
Misterbianco (CT), Italy
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Istituto Nazionale IRCCS Tumori Fondazione Pascale
Naples, Italy
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Ospedale San Raffaele
Milan, Italy
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Ospedale San Raffaele
Milan, Italy
PALbociclib CoLlaborative Adjuvant Study
Ospedale San Raffaele
Milan, Italy
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Humanitas Istituto Clinico Catanese
Misterbianco, Italy
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Humanitas Istituto Clinico Catanese
Misterbianco, Italy
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari
Bari, Italy
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi IRCCS
Bologna, Italy
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Istituto Nazionale per la Ricerca sul Cancro di Genova
Genova, Italy
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Istituto Nazionale Tumori Fondazione G Pascale
Naples, Italy
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
IOV - Istituto Oncologico Veneto IRCCS
Padova, Italy
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Nuovo Ospedale di Prato
Prato, Italy
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza
Rome, Italy
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Ospedale Santa Chiara
Trento, Italy
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Research Site
Naples, Italy
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Research Site
Naples, Italy
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Research Site
Naples, Italy
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Research Site
Naples, Italy
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
Research Site
Naples, Italy
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Research Site
Naples, Italy
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Research Site
Naples, Italy
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Research Site
Naples, Italy
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Research Site
Naples, Italy
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Research Site
Naples, Italy
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Research Site
Naples, Italy
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Research Site
Naples, Italy
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
Research Site
Naples, Italy
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Research Site
Naples, Italy
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Research Site
Naples, Italy
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Research Site
Naples, Italy
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Research Site
Naples, Italy
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Research Site
Naples, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Naples, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Research Site
Naples, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Naples, Italy
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Research Site
Naples, Italy
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
Research Site
Naples, Italy
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
Research Site
Naples, Italy
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Research Site
Milan, Italy
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Research Site
Milan, Italy
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Research Site
Milan, Italy
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Research Site
Milan, Italy
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
Research Site
Milan, Italy
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Research Site
Milan, Italy
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Research Site
Milan, Italy
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Research Site
Milan, Italy
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Research Site
Milan, Italy
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Research Site
Milan, Italy
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Research Site
Milan, Italy
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
Research Site
Milan, Italy
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Research Site
Milan, Italy
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Research Site
Milan, Italy
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Research Site
Milan, Italy
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Research Site
Milan, Italy
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Research Site
Milan, Italy
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Research Site
Milan, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Milan, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Research Site
Milan, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Milan, Italy
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Research Site
Milan, Italy
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
Research Site
Milan, Italy
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
Research Site
Milan, Italy
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Research Site
Roma, Italy
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Research Site
Roma, Italy
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Research Site
Roma, Italy
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Research Site
Roma, Italy
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Research Site
Roma, Italy
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Research Site
Roma, Italy
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Research Site
Roma, Italy
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Research Site
Roma, Italy
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
Research Site
Roma, Italy
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Research Site
Roma, Italy
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Research Site
Roma, Italy
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Research Site
Roma, Italy
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Research Site
Roma, Italy
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Research Site
Roma, Italy
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Research Site
Roma, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Roma, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Research Site
Roma, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Bologna, Italy
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Research Site
Bologna, Italy
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
Research Site
Bologna, Italy
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Research Site
Bologna, Italy
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Research Site
Bologna, Italy
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Research Site
Bologna, Italy
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Research Site
Bologna, Italy
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Research Site
Bologna, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Bologna, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Research Site
Bologna, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Brescia, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Brescia, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Research Site
Brescia, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Padova, Italy
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Research Site
Padova, Italy
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Research Site
Padova, Italy
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Research Site
Padova, Italy
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Research Site
Padova, Italy
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
Research Site
Padova, Italy
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Research Site
Padova, Italy
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Research Site
Padova, Italy
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Research Site
Padova, Italy
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Research Site
Padova, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Research Site
Padova, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Torino, Italy
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Research Site
Torino, Italy
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Research Site
Torino, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Torino, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Ancona, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Ancona, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Lecco, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Lecco, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Lecce, Italy
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Research Site
Lecce, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Candiolo, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Catania, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Research Site
Verona, Italy
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Lazio, Italy
THE-0504 in Patients With Solid Tumors
ASST degli Spedali Civili di Brescia
Brescia, Italy
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Istituto Europeo di Oncologia (IEO)
Milan, Italy
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Istituto Nazionale Tumori "Fondazione PASCALE"
Naples, Italy
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Ospedale Infermi di Rimini - Azienda Unita Sanitaria Locale Della Romagna
Rimini, Italy
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Azienda Ospedaliero-Universitaria di Ferrara
Ferrara, Italy
PALbociclib CoLlaborative Adjuvant Study
Azienda Ospedaliero-Universitaria Careggi/Florence University/Radiation Oncology Unit
Florence, Italy
PALbociclib CoLlaborative Adjuvant Study
Department of Internal Medicine (DIMI) - IRCCS San Martino University Hospital
Genoa, Italy
PALbociclib CoLlaborative Adjuvant Study
P.O. Misericordia AUSL Toscana Sud Est
Grosseto, Italy
PALbociclib CoLlaborative Adjuvant Study
Ospedale "Mater Salutis" di Legnago, Dept. of Medical Oncology
Legnago, Italy
PALbociclib CoLlaborative Adjuvant Study
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS
Meldola, Italy
PALbociclib CoLlaborative Adjuvant Study
Policlinico di Monza - Istituto di Oncologia del Policlinico di Monza
Monza, Italy
PALbociclib CoLlaborative Adjuvant Study
Medical Oncology Unit; University Hospital of Parma (Azienda Ospedaliero-Universitaria di Parma)
Parma, Italy
PALbociclib CoLlaborative Adjuvant Study
Nuovo Ospedale di Prato (NOP) - Azienda USL4 Prato
Prato, Italy
PALbociclib CoLlaborative Adjuvant Study
ASST Bergamo Ovest
Treviglio, Italy
PALbociclib CoLlaborative Adjuvant Study
S. Anna Hospital (Ospedale Sant'Anna)- Turin
Turin, Italy
PALbociclib CoLlaborative Adjuvant Study
IRCCS Ospedale San Raffaele
Milan, MI, Italy
18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer
Research Site
Rozzano, Italy
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Research Site
Rozzano, Italy
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Research Site
Rozzano, Italy
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Research Site
Rozzano, Italy
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Research Site
Rozzano, Italy
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Research Site
Rozzano, Italy
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Research Site
Rozzano, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Rozzano, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Research Site
Genova, Italy
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Research Site
Genova, Italy
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Research Site
Genova, Italy
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Research Site
Genova, Italy
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Research Site
Genova, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Genova, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Research Site
Meldola, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Meldola, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Research Site
Messina, Italy
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Research Site
Messina, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Research Site
Livorno, Italy
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Research Site
Livorno, Italy
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Research Site
Livorno, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Research Site
Florence, Italy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
IRCCS AOU di Bologna - Policlinico di Sant'Orsola
Bologna, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
AUSL Romagna - Presidio Ospedaliero Morgagni-Pierantoni
Forlì, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
European Institute of Oncology
Milan, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
Fondazione IRCCS Istituto Nazionale Tumori di Milano
Milan, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
Azienda Ospedaliera Universitaria Federico II
Naples, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
Presidio Ospedaliero "G. Bernabeo"
Ortona, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
Policlinico San Matteo
Pavia, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
Azienda Ospedaliera Universitaria Pisana
Pisa, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
AO San Giovanni Addolorata
Roma, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
IRCCS Humanitas Research Hospital
Rozzano, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
Azienda sanitaria universitaria Giuliano Isontina
Trieste, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi
Varese, Italy, Italy
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati
Avellino, Campania, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
Naples, Campania, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
IRCCS Azienda Ospedaliero Universitaria di Bologna
Bologna, Emilia-Romagna, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
Meldola, Emilia-Romagna, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Arcispedale Santa Maria Nuova
Reggio Emilia, Emilia-Romagna, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Fondazione Policlinico Universitario A Gemelli
Roma, Emilia-Romagna, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Ospedale San Raffaele S.r.l. - PPDS
Milan, Lombardy, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Istituto Nazionale Tumori Regina Elena
Milan, Lombardy, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda
Milan, Lombardy, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Istituto Clinico Humanitas
Rozzano (MI), Lombardy, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Ospedale San Giuseppe
Empoli, Tuscany, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Azienda Usl Toscana nord ovest - Ospedali Riuniti di Livorno
Livorno, Tuscany, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Azienda Ospedaliero Universitaria Pisana
Pisa, Tuscany, Italy
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Azienda Ospedaliero - Universitaria di Modena Policlinico
Modena, Emilia-Romagna, Italy
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Istituto Nazionale Tumori Regina Elena IRCCS
Rome, Lazio, Italy
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
IRCCS AOM Azienda Ospedaliera Metropolitana
Genoa, Liguria, Italy
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Asst Grande Ospedale Metropolitano Niguarda
Milan, Lombardy, Italy
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Azienda Ospedaliero Universitaria Ospedali Riuniti
Torrette Di Ancona, The Marches, Italy
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
"Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Trento"
Verona, Veneto, Italy
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Azienda Ospedaliero-Universitaria di Modena
Modena, Italy
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Azienda Ospedaliero-Universitaria di Modena
Modena, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, Italy
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Study of INCB123667 in Subjects With Advanced Solid Tumors
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
IRCCS Ospedale San Raffaele
Milan, Italy
Safety and Performance of REGENERA Breast Implant in Women Affected by Malignant Breast Lesion Treated by Lumpectomy
IRCCS Ospedale San Raffaele
Milan, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Ospedale Policlinico San Martino
Genova, Italy
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Ospedale Policlinico San Martino
Genova, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Ospedali Riuniti di Ancona
Ancona, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
CRO (Centro di Riferimento Oncologico)
Aviano, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Azienda Usl Toscana centro - Ospedale Santa Maria Annunziata
Bagno a Ripoli, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
IRCCS Istituto Tumori Giovanni Paolo II
Bari, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
ASST Papa Giovanni XXIII
Bergamo, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
ASST Spedali Civili
Brescia, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Ospedale A. Perrino
Brindisi, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
ASST della Valle Olona
Busto Arsizio, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Ospedale Valduce
Como, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Ospedale Careggi
Florence, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
AOU Gaetano Martino di Messina
Messina, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
European Institute of Oncology
Milan, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
ASST Fatebenefratelli Sacco
Milan, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Ospedale Niguarda
Milan, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Ospedale San Giuseppe MultiMedica
Milan, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Policlinico di Milano
Milan, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Azienda Ospedaliera Universitaria Federico II
Naples, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Ospedale Maggiore di Novara
Novara, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Policlinico Universitario Paolo Giaccone
Palermo, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Policlinico San Matteo
Pavia, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Azienda Usl Toscana centro - Ospedale di Prato Santo Stefano
Prato, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Ospedale Infermi
Rimini, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Policlinico Universitario Campus Bio-Medico
Roma, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Policlinico Umberto I
Rome, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Azienda Ospedaliero Universitaria di Sassari
Sassari, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
ASL CN2 - Ospedale Michele e Pietro Ferrero
Verduno, Italy
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy